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Psychedelics (Psilocybin, LSD) 
Primarily 
serotonergic, acting as 
agonists at 5-HT2A 
receptor subtypes 
(among others) 
Structural 
similarities  
between 
psychedelics 
and serotonin 
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• Psychoactive agent in over 100 species of 
mushrooms, most in Psilocybe genus 
Psilocybin (O-phosphoryl-4-hydroxy- 
N,N-dimethyltryptamine) 
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Psychedelics = Mind manifesting? 
“To fathom hell, or soar angelic, take a pinch of psychedelic.”  
   -Dr. Humphrey Osmond in a letter to Aldous Huxley, (1957) 
From Greek ‘psyche’ for mind, and ‘delos’ for manifest. 
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Psychedelics 
“A psychedelic drug is one which has small likelihood 
of causing physical addiction, craving, major 
physiological disturbances, delirium, disorientation, or 
amnesia, produces thought, mood, and perceptual 
changes otherwise rarely experienced except perhaps 
in dreams, contemplative and religious exaltation, 
flashes of vivid involuntary memory and acute 
psychoses.” 
           
           - Dr. Lester Grinspoon 
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• Initial psilocybin study in 36 healthy volunteers (2006) 
• 14 month persisting effects of psilocybin (2008) 
• Dose effects of psilocybin in 18 healthy volunteers (2011) 
• Effects of psilocybin on personality (2011) 
• Psilocybin for smoking cessation in 15 smokers (2014) 
• Psilocybin for anxiety in 44 cancer patients (2016) 
• Psilocybin’s effects on spirituality and meditation in 75 
healthy volunteers (2017) 
Research at Johns Hopkins 
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• The 8-hr drug sessions are conducted in a 
living-room-like environment   
• Two monitors are present throughout the 
session 
• Participants asked to: 
• lie on the couch 
• wear eye masks and headphones 
• listen to a program of music 
• focus attention inward 
• trust, let go, be open 
Drug Sessions 

Pahnke-Richards Mystical Experience Questionnaire –  
7 hours after session 
Change in 
Well-Being: 
2 Months after  
sessions 
Community ratings of participants’ behavior & 
attitudes 2 months after sessions 
Mystical-type 
experiences 
occasioned by 
psilocybin mediate 
the attribution of 
personal meaning 
and spiritual 
significance 14 
months later. 
Griffiths et al. (2006, 2008) 
20 
Psilocybin can change personality 
NEO Personality Inventory: Neuroticism, Openness, Extroversion, 
Agreeableness, and Conscientiousness 
Openness: aesthetic appreciation and sensitivity, imagination and fantasy, 
and broad-minded tolerance of others’ viewpoints and values 
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• 39% of participants (7 of 18) had extreme ratings 
of fear, fear of insanity, or feeling trapped 
• 6 cases:  30 mg/70 kg 
• 1 case:  20 mg/70 kg 
• Small increase in mystical experience scores 
• Potential for dangerous behavior if unsupervised 
• No recorded cases of HPPD in our studies (>700 
sessions with >300 participants). 
The Dark Side 
Unpredictable Timing 



Placebo
    
Psilocybin 



Meta-Analysis of controlled trials of LSD for Alcoholism: 
Across studies, LSD doubled the odds a patient would be 
alcohol free at the 1st follow up (N=536) 
Krebs T S , Johansen P J Psychopharmacol 2012;26:994-1002 
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• Open-label pilot 
study (N =10) of 1-2 
doses psilocybin + 
MET for alcohol 
dependence 
 
• Significantly 
decreased drinking 
up to 36 weeks later 
Bogenschutz et al. J Psychopharmacol.  
2015; 29(3): 289-299 
Psilocybin for Alcoholism 
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• Open-label pilot study   
(N =15) of 2-3 doses 
psilocybin + CBT for 
smoking cessation 
 
• 12 (80%) abstinent at 6mo. 
 
• 10 (67%) abstinent at 12mo. 
 
• 9 (60%) abstinent at ~30mo. 
Johnson et al., 2014, 2016.  
Garcia-Romeu et al., 2015 
Psilocybin Smoking Cessation 
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Linear regression of mystical experience 
and long-term change in cotinine
r = -0.55, p = 0.03
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High levels of personal meaning and mystical-type 
effects were associated with decreased craving, and 
increased confidence to abstain. 
 
How does it work? 
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Therapeutic infusions of ketamine: Do the 
psychoactive effects matter? 
E Dakwar, C Anerella, CL Hart, FR Levin et al. Drug & Alcohol Dependence, 2014. 
Nature Reviews | Neuroscience
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behaviour in response to DOI through  
sensitization of 5-HT
2
 receptor signalling in 
the PFC83. In humans, fronto-limbic 5-HT
2A
 
receptor density is correlated not only with 
anxiety but also with an individual’s difficul-
ties in coping with stress84. Indeed, recent 
studies showed that prefrontal 5-HT
2A
 recep-
tors located on descending projections that 
control serotonergic activity in the dorsal 
raphe are involved in stress responses67,85. 
Together, these findings suggest that down-
regulation of prefrontal 5-HT
2A
 receptors by 
classical hallucinogens might underlie some 
of the effects of hallucinogens on depression 
and anxiety.
Finally, with regard to the finding that 
LSD reduces anxiety and pain in cancer 
patients20, it is of note that prefrontal 5-HT
2A
 
density correlated with responses to tonic 
pain but not with responses to short pha-
sic pain stimuli. This suggests a role of the 
5-HT
2A
 receptors in the cognitive evaluation 
of pain experiences86 and points to addi-
tional therapeutic potential for hallucinogens 
in individuals with chronic pain.
Dissociative anaesthetics. At sub-anaesthetic 
doses, dissociative anaesthetics, such as 
ketamine, primarily block the NMDA recep-
tor at the PCP binding site in the receptor’s 
ionotropic channel14 (FIG. 1b). The psychoac-
tive potency of the s-ketamine enantiomer is 
three to four times higher than that of the 
r -ketamine enantiomer. This is paralleled by 
their relative affinities at the NMDA receptor 
complex87. Systemic administration of  
non-competitive NMDA antagonists, such  
as ketamine, PCP and MK-801 (also  
known as dizocilpine), in rats mark-
edly increases glutamate release in the 
mPFC88,89 concomitant with an increase in 
the firing rate of pyramidal neurons in this 
area90. These effects are probably due to a 
blockade of NMDA receptors on GABA 
(γ-aminobutyric acid)-ergic interneurons45,91 
in cortical and/or subcortical structures and 
to the subsequent reduction of inhibitory 
control over prefrontal glutamatergic neu-
rons92. The increased extracellular glutamate 
levels in the mPFC seem to contribute to the 
psychotropic effects of ketamine and PCP, 
as AMPA receptor antagonists88 or agonists 
of mGluR2 and mGluR3 (REF. 93) abolished 
various behavioural effects of NMDA 
antagonists in rats. Likewise, the behavioural 
effects of selective NR2B antagonists — such 
as CP-101,606 (also known as Traxoprodil), 
which produces dose-dependent psycho-
tropic effects similar to those of ketamine in 
humans94 — can be blocked by administra-
tion of AMPA receptor antagonists95. Finally, 
lamotrigine, which reduces presynaptic 
glutamate release, attenuated the subjective 
effects of s-ketamine in humans96.
In addition to having these glutamatergic 
effects, non-competitive NMDA receptor 
antagonists increase extracellular prefrontal 
and mesolimbic dopamine89,93 and pre-
frontal serotonin89 levels in rats, presum-
ably by stimulating corticofugal glutamate 
release in the VTA97 and the dorsal raphe89, 
respectively. Studies into the contribution of 
this dopaminergic and serotonergic activa-
tion to the behavioural effects of NMDA 
antagonists are scant and the results are 
somewhat controversial. Specifically, in 
two studies in humans, ketamine-induced 
striatal dopamine release correlated with 
the extent of ketamine-induced psychotic 
Figure 1 | Activation of the prefrontal network and glutamate release by psychedelics. a | The 
figure shows a model in which hallucinogens, such as psilocin, lysergic acid diethylamide (LSD) and 
dimethyltryptamine (DMT), increase extracellular glutamate levels in the prefrontal cortex through 
stimulation of postsynaptic serotonin (5-hydroxytryptamine) 2A (5-HT
2A
) receptors that are located 
on large glutamatergic pyramidal cells in deep cortical layers (V and VI) projecting to layer V pyramidal 
neurons. This glutamate release leads to an activation of AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid) and NMDA (N-methyl-d-aspartate) receptors on cortical pyramidal neurons. In 
addition, hallucinogens directly activate 5-HT
2A
 receptors located on cortical pyramidal neurons. This 
activation is thought to ultimately lead to increased expression of brain-derived neurotrophic factor 
(BDNF). b | The figure shows a model in which dissociative NMDA antagonists, such as ketamine, block 
inhibitory GABA (γ-aminobutyric acid)-ergic interneurons in cortical and subcortical brain areas, lead-
ing to enhanced firing of glutamatergic projection neurons and increased extracellular glutamate 
levels in the prefrontal cortex. As ketamine also blocks NMDA receptors on cortical pyramidal neurons, 
the increased glutamate release in the cortex is thought to stimulate cortical AMPA more than NMDA 
receptors. The increased AMPA-receptor-mediated throughput relative to NMDA-receptor-mediated 
throughput is thought ultimately to lead to increased expression of BDNF.
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Psychedelic drugs have long held a special 
fascination for mankind because they pro-
duce an altered state of consciousness that is 
characterized by distortions of perception, 
hallucinations or visions, ecstasy, dissolu-
tion of self boundaries and the experience 
of union with the world. As plant-derived 
materials, they have been used traditionally 
by many indigenous cultures in medical  
and religious practices for centuries, if  
not millennia1.
However, research into psychedelics 
did not begin until the 1950s after the 
breakthrough discovery of the classical 
hallucinogen lysergic acid diethylamide 
(LSD) by Albert Hofmann2 (TIMELINE). The 
classical hallucinogens include indoleam-
ines, such as psilocybin and LSD, and 
phenethylamines, such as mescaline and 
2,5-dimethoxy-4-iodo-amphetamine 
(DOI). Research into psychedelics was 
advanced in the mid 1960s by the finding 
that dissociative anaesthetics such as keta-
mine and phencyclidine (PCP) also pro-
duce psychedelic-like effects3 (BOX 1). Given 
their overlapping psychological effects, 
both classes of drugs are included here  
as psychedelics. 
Depending on the individual taking the 
drug, their expectations, the setting in which 
the drug is taken and the drug dose, psych-
edelics produce a wide range of experiential 
states, from feelings of boundlessness, unity 
and bliss on the one hand, to the anxiety-
inducing experiences of loss of ego-control 
and panic on the other hand4–7. Researchers 
from different theoretical disciplines and 
experimental perspectives have emphasized 
different experiential states. One emphasis 
has been placed on the LSD-induced percep-
tual distortions — including illusions and 
hallucinations, thought disorder and  
experiences of split ego7,8 — that are also 
seen in naturally occurring psychoses9–11. 
This perspective has prompted the use of 
psychedelics as research tools for unravelling 
the neuronal basis of psychotic disorders, 
such as schizophrenia spectrum disorder. 
The most recent work has provided com-
pelling evidence that classical hallucino-
gens primarily act as agonists of serotonin 
(5-hydroxytryptamine) 2A (5-HT
2A
)  
receptors12 and mimic mainly the so-
called positive symptoms (hallucinations 
and thought disorder) of schizophrenia10. 
Dissociative anaesthetics mimic the positive 
and the negative symptoms (social with-
drawal and apathy) of schizophrenia  
through antagonism at NMDA (N-methyl-d-
aspartate) glutamate receptors13,14.
Emphasis has also been placed on the 
early observation that LSD can enhance 
self-awareness and facilitate the recollection 
of, and release from, emotionally loaded 
memories15,16. This perspective appealed 
to psychiatrists as a unique property that 
could facilitate the psychodynamic process 
during psychotherapy. In fact, by 1965 there 
were more than 1,000 published clinical 
studies that reported promising therapeutic 
effects in over 40,000 subjects17. LSD,  
psilocybin and, sporadically, ketamine have 
been reported to have therapeutic effects in 
patients with anxiety and obsessive– 
compulsive disorders (OCD), depression, 
sexual dysfunction and alcohol addiction,  
and to relieve pain and anxiety in 
patients with terminal cancer18–23 (BOX 2). 
Unfortunately, throughout the 1960s and 
1970s LSD and related drugs became 
increasingly associated with cultural rebel-
lion; they were widely popularized as drugs 
of abuse and were depicted in the media as 
highly dangerous. Consequently, by about 
1970, LSD and related drugs were placed 
in Schedule I in many western countries. 
Accordingly, research on the effects of  
classical psychedelics in humans was 
severely restricted, funding became  
difficult and interests in the therapeutic  
use of these drugs faded, leaving many 
avenues of inquiry unexplored and  
many questions unanswered.
With the development of sophisticated 
neuroimaging and brain-mapping tech-
niques and with the increasing understand-
ing of the molecular mechanisms of action 
of psychedelics in animals, renewed interest 
in basic and clinical research with psyche-
delics in humans has steadily increased since 
the 1990s. In this Perspective, we review 
early and current findings of the therapeutic 
effects of psychedelics and their mechanisms 
of action in relation to modern concepts of 
the neurobiology of psychiatric disorders. 
We then evaluate the extent to which  
psychedelics may be useful in therapy — 
aside from their established application as 
models of psychosis3,11.
O PI NI O N
The neurobiology of psychedelic 
drugs: implications for the treatment 
of mood disorders
Franz X. Vollenweider and Michael Kometer
Abstract | After a pause of nearly 40 years in research into the effects of psychedelic 
drugs, recent advances in our understanding of the neurobiology of psychedelics, 
such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to 
renewed interest in the clinical potential of psychedelics in the treatment of various 
psychiatric disorders. Recent behavioural and neuroimaging data show that 
psychedelics modulate neural circuits that have been implicated in mood and 
affective disorders, and can reduce the clinical symptoms of these disorders. These 
findings raise the possibility that research into psychedelics might identify novel 
therapeutic mechanisms and approaches that are based on glutamate-driven 
neuroplasticity.
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receptor density is correlated not only with 
anxiety but also with an individual’s difficul-
ties in coping with stress84. Indeed, recent 
studies showed that prefrontal 5-HT
2A
 recep-
tors located on descending projections that 
control serotonergic activity in the dorsal 
raphe are involved in stress responses67,85. 
Together, these findings suggest that down-
regulation of prefrontal 5-HT
2A
 receptors by 
classical hallucinogens might underlie some 
of the effects of hallucinogens on depression 
and anxiety.
Finally, with regard to the finding that 
LSD reduces anxiety and pain in cancer 
patients20, it is of note that prefrontal 5-HT
2A
 
density correlated with responses to tonic 
pain but not with responses to short pha-
sic pain stimuli. This suggests a role of the 
5-HT
2A
 receptors in the cognitive evaluation 
of pain experiences86 and points to addi-
tional therapeutic potential for hallucinogens 
in individuals with chronic pain.
Dissociative anaesthetics. At sub-anaesthetic 
doses, dissociative anaesthetics, such as 
ketamine, primarily block the NMDA recep-
tor at the PCP binding site in the receptor’s 
ionotropic channel14 (FIG. 1b). The psychoac-
tive potency of the s-ketamine enantiomer is 
three to four times higher than that of the 
r -ketamine enantiomer. This is paralleled by 
their relative affinities at the NMDA receptor 
complex87. Systemic administration of  
non-competitive NMDA antagonists, such  
as ketamine, PCP and MK-801 (also  
known as dizocilpine), in rats mark-
edly increases glutamate release in the 
mPFC88,89 concomitant with an increase in 
the firing rate of pyramidal neurons in this 
area90. These effects are probably due to a 
blockade of NMDA receptors on GABA 
(γ-aminobutyric acid)-ergic interneurons45,91 
in cortical and/or subcortical structures and 
to the subsequent reduction of inhibitory 
control over prefrontal glutamatergic neu-
rons92. The increased extracellular glutamate 
levels in the mPFC seem to contribute to the 
psychotropic effects of ketamine and PCP, 
as AMPA receptor antagonists88 or agonists 
of mGluR2 and mGluR3 (REF. 93) abolished 
various behavioural effects of NMDA 
antagonists in rats. Likewise, the behavioural 
effects of selective NR2B antagonists — such 
as CP-101,606 (also known as Traxoprodil), 
which produces dose-dependent psycho-
tropic effects similar to those of ketamine in 
humans94 — can be blocked by administra-
tion of AMPA receptor antagonists95. Finally, 
lamotrigine, which reduces presynaptic 
glutamate release, attenuated the subjective 
effects of s-ketamine in humans96.
In addition to having these glutamatergic 
effects, non-competitive NMDA receptor 
antagonists increase extracellular prefrontal 
and mesolimbic dopamine89,93 and pre-
frontal serotonin89 levels in rats, presum-
ably by stimulating corticofugal glutamate 
release in the VTA97 and the dorsal raphe89, 
respectively. Studies into the contribution of 
this dopaminergic and serotonergic activa-
tion to the behavioural effects of NMDA 
antagonists are scant and the results are 
somewhat controversial. Specifically, in 
two studies in humans, ketamine-induced 
striatal dopamine release correlated with 
the extent of ketamine-induced psychotic 
Figure 1 | Activation of the prefrontal network and glutamate release by psychedelics. a | The 
figure shows a model in which hallucinogens, such as psilocin, lysergic acid diethylamide (LSD) and 
dimethyltryptamine (DMT), increase extracellular glutamate levels in the prefrontal cortex through 
stimulation of postsynaptic serotonin (5-hydroxytryptamine) 2A (5-HT
2A
) receptors that are located 
on large glutamatergic pyramidal cells in deep cortical layers (V and VI) projecting to layer V pyramidal 
neurons. This glutamate release leads to an activation of AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid) and NMDA (N-methyl-d-aspartate) receptors on cortical pyramidal neurons. In 
addition, hallucinogens directly activate 5-HT
2A
 receptors located on cortical pyramidal neurons. This 
activation is thought to ultimately lead to increased expression of brain-derived neurotrophic factor 
(BDNF). b | The figure shows a model in which dissociative NMDA antagonists, such as ketamine, block 
inhibitory GABA (γ-aminobutyric acid)-ergic interneurons in cortical and subcortical brain areas, lead-
ing to enhanced firing of glutamatergic projection neurons and increased extracellular glutamate 
levels in the prefrontal cortex. As ketamine also blocks NMDA receptors on cortical pyramidal neurons, 
the increased glutamate release in the cortex is thought to stimulate cortical AMPA more than NMDA 
receptors. The increased AMPA-receptor-mediated throughput relative to NMDA-receptor-mediated 
throughput is thought ultimately to lead to increased expression of BDNF.
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Psychedelic drugs have long held a special 
fascination for mankind because they pro-
duce an altered state of consciousness that is 
characterized by distortions of perception, 
hallucinations or visions, ecstasy, dissolu-
tion of self boundaries and the experience 
of union with the world. As plant-derived 
materials, they have been used traditionally 
by many indigenous cultures in medical  
and religious practices for centuries, if  
not millennia1.
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phenethylamines, such as mescaline and 
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advanced in the mid 1960s by the finding 
that dissociative anaesthetics such as keta-
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duce psychedelic-like effects3 (BOX 1). Given 
their overlapping psychological effects, 
both classes of drugs are included here  
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Depending on the individual taking the 
drug, their expectations, the setting in which 
the drug is taken and the drug dose, psych-
edelics produce a wide range of experiential 
states, from feelings of boundlessness, unity 
and bliss on the one hand, to the anxiety-
inducing experiences of loss of ego-control 
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has been placed on the LSD-induced percep-
t al distortion  — including illusions and 
hallucinations, thought disorder and  
experiences of split ego7,8 — that are also 
seen in naturally occurring psychoses9–11. 
This perspective has prompted the use of 
psychedelics as research tools for unravelling 
the neuronal basis of psychotic disorders, 
such as schizophrenia spectrum disord r. 
The most recent work has provided com-
pelling evidence that classical hallucino-
gens primarily act as agonists of serotonin 
(5-hydroxytryptamine) 2A (5-HT
2A
)  
receptors12 and mimic mainly the so-
called positive symptoms (hallucinations 
and thought disorder) of schizophrenia10. 
Dissociative anaesthetics mimic the positive 
and the negative symptoms (social with-
drawal and apathy) of schizophrenia  
through antagonism at NMDA (N-methyl-d-
aspartate) glutamate receptors13,14.
Emphasis has also been placed on the 
early observation that LSD can enhance 
self-awareness and facilitate the recollection 
of, and release from, emotionally loaded 
memories15,16. This perspective appealed 
to psychiatrists as a unique property that 
could facilitate the psychodynamic process 
during psychotherapy. In fact, by 1965 there 
were more than 1,000 published clinical 
studies that reported promising therapeutic 
effects in over 40,000 subjects17. LSD,  
psilocybin and, sporadically, ketamine have 
been reported to have therapeutic effects in 
patients with anxiety and obsessive– 
compulsive disorders (OCD), depression, 
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and to relieve pain and anxiety in 
patients with terminal cancer18–23 (BOX 2). 
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of abuse and were depicted in the media as 
highly dangerous. Consequently, by about 
1970, LSD and related drugs were placed 
in Schedule I in many western countries. 
Accordingly, research on the effects of  
classical psychedelics in humans was 
severely restricted, funding became  
difficult and interests in the therapeutic  
use of these drugs faded, leaving many 
avenues of inquiry unexplored and  
many questions unanswered.
With the d velopment of sophisticated 
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niques and with the increasing understand-
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of psychedelics in animals, renewed interest 
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aside from their established application as 
models of psychosis3,11.
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Fig. 1. Behavioral response to hallucinogens DOI and LSD. Wild type and mGluR2-
KO mice (n = 4–5 per treatment group) w ere injected w ith vehicle, DOI (2 mg/kg)
or LSD (0.24 mg/kg), and the head-tw itch response w as scored 15 min after injec-
t ion for 30 min. ***p < 0.001; Bonferroni’s post hoc test of tw o-w ay ANOVA. Data are
means ± S.E.M. n.s., not signiﬁ cant.
We ﬁ rst assayed the head-tw itch response induced by DOI and
LSD in w ild type and mGluR2-KO mice (Fig. 1). Tw o-w ay ANOVA
indicated a stat ist ical signiﬁcance for the effects of the treatment
[F(2,19) = 31.05; p < 0.001] and genotype [F(1,19) = 74.10; p < 0.001].
Signiﬁcance w as also found for the interact ion betw een treat-
ment and genotype [F(2,19) = 20.05; p < 0.001]. The post hoc analysis
revealed that DOI and LSD act ivated a signiﬁcant head-tw itch
response in w ild type mice (p < 0.001). Notably, no signiﬁcant head-
tw itch response w as detected in mGluR2-KO mice for any of these
tw o agonists (p > 0.05).
The decreased head-tw itch response fol low ing administ ra-
t ion of hallucinogens led us to examine the level of expression
of 5-HT2AR in mGluR2-KO mice. Equil ibrium binding saturat ion
experiments w ere performed to determine the binding afﬁnity
(KD) and receptor density (Bmax ) of 5-HT2ARs in w ild type and
mGluR2-KO mouse frontal cortex membrane preparat ions (Fig. 2;
Fig. 2. Expression of 5-HT2AR in mGluR2-KO mice. [3 H]Ketanserin binding satu-
rat ion curves in w ild type (black) and mGluR2-KO (w hite) mouse frontal cortex
membrane preparat ions (n = 6 per group). Data are means ± S.E.M.
for experimental detai ls, see [14] ). Neither Bmax nor KD values of
the binding of [3H]ketanserin, a 5-HT2AR antagonist , w ere sig-
niﬁ cant ly changed in mGluR2-KO mice, w hich demonstrates that
level of expression of 5-HT2AR is not affected in the absence of
mGluR2 (Bmax : w i ld type, 724.5 ± 93 fmol/mg protein; mGluR2-KO,
701.5 ± 80 fmol/mg protein. KD : w i ld type, 2.27 ± 0.8 nM; mGluR2-
KO, 2.30 ± 0.71 nM).
We next determined the afﬁ nity of the mGlu2/3 agonist
LY379269 displacing [3H]LY341495 in w ild type and 5-HT2AR-KO
mice (Fig. 3A), and that of the 5-HT2AR agonist DOI displac-
ing [3H]ketanserin binding in w ild type and mGluR2-KO mice
(Fig. 3B; for experimental detai ls, see [14] ). Compet it ion binding
experiments of [3H]LY341495 w ere best described by a tw o-site
model in w ild type mouse frontal cortex membrane preparat ions
[F(2,28) = 4.71; p < 0.05]. How ever, displacement of [3H]LY341495
binding by LY379268 w as best described by a one-site model in 5-
HT2AR-KO mice [F(2,16) = 0.62; p = 0.55]. The low afﬁnity binding
site for LY379268 did not differ betw een w ild type and 5-HT2AR-
KO mice (Fig. 3A). Sim ilarly, compet it ion binding experiments of
Fig. 3. Cellular response to hallucinogenic 5-HT2AR agonist DOI. (A) LY379268 displacement of [3 H]LY341495 binding w as performed in w ild type (black) and 5-HT2AR-KO
(w hite) mouse frontal cortex membrane preparat ions. Competit ion curves w ere analyzed by nonlinear regression to derive dissociat ion constants for the high and low
afﬁ nity states of the receptor. One-site model or tw o-site model as a better descript ion of the data w as determined by F test. Tw o-site model, p < 0.001. A tw o-site model
provided a better descript ion of the data in w ild type mice. W ild type mice: Ki -high (log M), − 9.51 ± 0.45; Ki - low (log M), − 7.95 ± 0.26; %high-afﬁ nity binding sites, 36.6 ± 1;
and 5HT2AR-KO mice: Ki - low (log M), − 7.60 ± 0.07 (n = 3–5). (B) DOI displacement of [
3H]ketanserin binding w as performed in w ild type (black) and mGluR2-KO (w hite)
mouse frontal cortex membrane preparat ions. A tw o-site model provided a better descript ion of the data in w ild type mice. W ild type mice: Ki -high (log M), − 8.56 ± 0.28;
Ki - low (log M), − 6.31 ± 0.16; %high-afﬁ nity binding sites, 35.9 ± 4; and mGluR2-KO mice: Ki - low (log M), − 6.72 ± 0.08 (n = 5–6). (C) Cellular response in mouse frontal cortex
assayed by qRT-PCR. Wild type or mGluR2-KO mice w ere injected w ith vehicle (w hite) or DOI (black; 2 mg/kg). Changes in expression levels are reported as fold change over
vehicle. *p < 0.05; ***p < 0.001; Bonferroni’s post-hoc test of tw o-factor ANOVA (n = 5–6 per group). Data are means ± S.E.M. n.s., not signiﬁ cant.

Table 2. Verbatim written comments for all volunteers who demonstrated biologically verified 
smoking abstinence at 6-month follow-up (n=12). These comments were excerpted from the 
States of Consciousness Retrospective Questionnaire (administered at end of treatment, in week 
15) that asked open-ended questions about what was most memorable and what was most 
spiritually significant about the psilocybin session experiences.  
______________________________________________________________________________ 
Participant ID Verbatim Comments 
______________________________________________________________________________  
402  Feelings of gratefulness, a great (powerful) remembrance of humility… of my   
  experience of being, the experience of my being in and within the infinite. 
 
403  Not at all religious but significant in motivating me to nurture my spiritual life. 
 
405   It changes what I believe… We are all one and divine. 
 
406 
1
  The awareness that all is one and then the realization that I am an integral piece of the  
  one's puzzle. 
 
410  Oneness with universe; being forgiven. 
 
413  Rich joy and awe. My body melting and becoming one with the universe felt both  
  painless and profound… Feeling complete as a person and physically a part of all thin  
 
416  There is a meaningful presence that humbles any human heart. 
 
417  Simultaneously being aware and saturated in the majesty of existence. 
 
421  Seeing God speaks for itself; seeing and feeling forever was like traveling through  
  space-time. 
 
422  The sessions permitted me to go inside and see and feel the nature of the mind. 
 
423  Recognizing the source and manifestation of visions… source of unconscious content. 
 
427  I believe I channeled the power of the Goddess and that I hold that power in me. I  
  believe she exists everywhere and I look for her to add spark, life, and joy to   
  everyday ordinary situations. 
_____________________________________________________________________________ 
1 
This participant was out of the country at end of treatment, and provided these retrospective comments 
at 12-month follow-up. 
 
“The ability of psychedelics to elicit mystical, transcendent, or peak 
experiences has also been proposed as a potential psychological 
mechanism in precipitating insight and behavior change… the 
psychedelic-occasioned peak experience may function as a salient, 
discrete event producing inverse PTSD- like effects- that is, persisting 
changes in behavior (and presumably the brain) associated with 
lasting benefit.”  
             (Garcia-Romeu et al., 2014) 
 
Psilocybin-assisted Smoking 
Cessation follow-up RCT 
• Randomized controlled trial 
• Participants receive 4 sessions CBT for smoking 
cessation prior to a Target Quit Date in week 5 
• Randomly assigned to receive 1 high dose of 
psilocybin or 8-10 weeks of nicotine patch 
• Follow up meetings continue weekly or biweekly 
until 8 weeks post-quit, and 3, 6, 12 months. 
• MRI scans occur in weeks 2 (pre), 5 (24 hours 
post-quit), and 19 (3 months post-quit for abstinent 
individuals) 
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